Impact of Achieved Blood Pressures on Mortality Risk and End-Stage Renal Disease Among a Large, Diverse Hypertension Population
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background Medical literature or clinical guidelines have not adequately addressed the ideal blood pressure (BP) treatment targets for survival and renal outcome. Objective To evaluate ranges of treated BP in a large hypertension population and compare risk of mortality and end stage renal disease (ESRD). Methods A retrospective cohort study within the Kaiser Permanente Southern California health system was performed from January 1, 2006 to December 31, 2010. Treated hypertensive individuals age >/=18 years were studied. Cox proportional hazards regression models were used to evaluate the risks (hazard ratios) for mortality and/or ESRD among different BP categories with and without stratification for diabetes mellitus (DM) and older age. Results Among 398,419 treated hypertensive individuals (30% with DM), mortality occurred in 25,182 (6.3%) and ESRD in 4,957 (1.2%). Adjusted HR (95% CI) for composite mortality/ESRD in systolic BPs <110, 110-119, 120-129, 140-149, 150-159, 160-169, and >/=170 compared to 130-139 mmHg were 4.1 (3.8,1.3), 1.8 (1.7,1.9), 1.1 (1.1,1.1), 1.4 (1.4,1.5), 2.3 (2.2,2.5), 3.3 (3.0,3.6), and 4.9 (4.4,5.5) respectively. Diastolic BPs 60-79 mmHg were associated with the lowest risk. The nadir systolic and diastolic BP for the lowest risk was 137 and 71 mmHg respectively. Stratified analyses revealed that the DM population had a similar HR curve but a lower nadir at 131 and 69 mmHg but age >/=70 had a higher nadir (140 and 70 mmHg). Conclusions Both higher and lower treated BPs compared to 130-139 mmHg systolic and 60-79 mmHg diastolic ranges had worsened outcomes. Our study adds to the growing uncertainty about BP treatment targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598 · cited 1×
“SBP = systolic blood pressure In high-risk populations, such as those with diabetes mellitus (DM) and chronic kidney disease (CKD), interventions to lower BP below current target levels have not demonstrated outcome improvements (14,19,25).”
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008
Egan, B. M. (2010) · JAMA · doi:10.1001/jama.2010.650 · Cited by 2,197
Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease: A Cohort Study
Kovesdy, C. P., Bleyer, A. J., Molnar, M. Z., Ma, J. Z., Sim, J. J., Cushman, W. C., Quarles, L. D., & Kalantar-Zadeh, K. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00004 · Cited by 213
Self-citation
Cited by
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00519-5 · Cited by 1,461
Self-citationArterial hypertension in adults. Clinical guidelines 2020
Kobalava, Z. D., Konradi, A. O., Nedogoda, S. V., Shlyakhto, E. V., Arutyunov, G. P., Baranova, E. I., Barbarash, O. L., Boitsov, S. A., Vavilova, T. V., Villevalde, S. V., et al. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-3-3786 · Cited by 541
Vidal-Petiot, E., Ford, I., Greenlaw, N., Ferrari, R., Fox, K. M., Tardif, J.-C., Tendera, M., Tavazzi, L., Bhatt, D. L., & Steg, P. G. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31326-5 · Cited by 470
Metadata
- Authors
- Sim, J. J., Shi, J., Kovesdy, C. P., Kalantar-Zadeh, K., & Jacobsen, S. J.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 64
- Issue
- 6
- Pages
- 588-597
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2065564595
- Cited by
- 160
- References
- 11
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.